Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

SEPTEMBER 13, 2022

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. However, myelodysplastic syndromes and myeloproliferative neoplasms are also prominent types of blood cancer.

Genome Project 92

Genome Project Genome Genomics DNA 92

Drug Discovery World

FEBRUARY 15, 2023

These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Besides spheroids, another area of interest is antibody-directed cell cytotoxicity (ADCC). doi:10.15252/emmm.201606857pmid:[link]

Research 52

Research In-Vitro In-Vivo Development 52